GlassScriptPhysician profile
Chope T Archuleta
NPI 1720019201
$366.96
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $145.14 | 2019 | |
| Novo Nordisk INC | $96.28 | 2019 | |
| Lilly USA, LLC | $40.90 | 2019 | |
| Rare Disease Therapeutics, INC. | $22.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.79 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.28 | 2019 | |
| Mylan Specialty L.P. | $12.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chope Archuleta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.